Bullish
Eli Lilly's Jaypirca approved as first-line treatment for CLL/SLL
Eli Lilly's Jaypirca (pirtobrutinib) has received FDA approval as a first-line treatment for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not been previously treated and do not have a known 17p deletion. This approval is expected to expand the drug's market potential and strengthen Lilly's oncology portfolio.
Key points
- FDA approves Jaypirca as first-line treatment for CLL/SLL
Sources
AI-generated from public news sources. Not financial advice.
